IRI+Tmab併用療法の進行・再発HER2陽性胃癌既治療例に対する多施設第II相試験：OGSG1203 (HERBIS-5)

FU, IRI, OX不応KRAS野生型mCRCに対するIRI+Panitumumab 療法の日本人データ (OGSG1001)

自主的地域型臨床試験グループOGSGの実績と将来展望

Randomized phase II study of docetaxel vs Paclitaxel for patients with advanced or recurrent esophageal cancer who previously received fluoropyrimidine and platinum-based chemotherapy (OGSG1201)

Randomized phase II study of CPT-11 versus PTX versus each combination chemotherapy with S-1 in patients with advanced gastric cancer refractory to S-1 or S-1 plus platinum (OGSG0701)

Randomized phase II study of CPT-11 versus PTX versus each combination chemotherapy with S-1 in patients with advanced gastric cancer refractory to S-1 or S-1 plus CDDP（OGSG0701）

Five-year outcome of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for Stage III gastric cancer after curative D2 gastrectomy (OGSG0604)

A randomized phase II factorial design trial of CPT-11 versus PTX versus each combination with S-1 in patients with advanced gastric cancer refractory to S-1: Final results of OGSG0701

A phase II study of panitumumab plus irinotecan for metastatic colorectal cancer with wild KRAS exon 2, resistant to fluoropyrimidine, oxaliplatin, and irinotecan in Japanese. Osaka Gastrointestinal cancer chemotherapy Study Group:（OGSG1001）

Phase II feasibility study of adjuvant S-1 plus docetaxel repeated for 6 months as adjuvant chemotherapy for Stage III gastric cancer after curative D2 gastrectomy (OGSG 1002)